I'm LongbridgeAI, I can summarize articles.DualityBio (9606.HK) fell more than 6% in Hong Kong trading to a record low of HK$95.95.
The stock is down 7.92% over the past five sessions and down 67.82% year to date. It sits 74.54% below its 52-week high of HK$376.80. Volume was 0.48 times its average.
The Hang Seng Index is down 2.78% over the past five sessions and down 7.26% year to date.
The biotechnology industry index fell 3.6% over the same period.
An interim analysis of a Phase III trial for the company's core drug, patritumab deruxtecan, missed expectations. While the study met its primary endpoint of progression-free survival, the improvement was modest and the incidence of interstitial lung disease was elevated, limiting the clinical benefit.
Based on public media reports. AI-generated; not investment advice.
